Current perspectives on congenital long QT syndrome

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Congenital long QT syndrome (LQTS) is a genetic disorder linked to cardiac ion channel gene mutations.
• These mutations disrupt cardiac myocyte action potentials, raising the risk of fatal ventricular arrhythmias and sudden cardiac death.
• Clinical presentations vary widely, complicating diagnosis, and QT intervals can fluctuate, necessitating further investigation.

Purpose of the Study:

• To review the genetic basis, diagnostic challenges, and current management strategies for congenital long QT syndrome.
• To highlight the role of genetic testing in identifying causative mutations and facilitating family member screening.
• To discuss limitations of current genetic panels and future directions in genotype-guided therapy and risk stratification.

Main Methods:

• Review of existing literature on congenital long QT syndrome.
• Analysis of diagnostic criteria and challenges associated with varying clinical presentations.
• Evaluation of current treatment modalities, including beta-blocker therapy and implantable cardioverter-defibrillators (ICDs).

Main Results:

• Genetic mutations in cardiac ion channels are the primary cause of LQTS.
• Genetic testing can identify known mutations but may yield false negatives for rare variants.
• Beta-blockers are standard treatment; ICDs are indicated for high-risk patients.

Conclusions:

• Accurate diagnosis of LQTS requires integrating clinical, electrocardiographic, and genetic data.
• Future research should focus on genotype-guided risk stratification for ICD implantation and developing genotype-specific pharmacological treatments.